Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

News Daily News

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

June 05, 2024

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

News Daily News

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Michael O'Riordan

February 18, 2022

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

News Conference News ACC 2019

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Michael O'Riordan

March 17, 2019

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

News Conference News AHA 2018

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

Michael O'Riordan

November 12, 2018

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

News Daily News

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

Michael O'Riordan

April 17, 2018

News Daily News

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

December 02, 2016

News Daily News

Increased Sedentary Time Ups Risk for CVD, Diabetes, and Death, the AHA Says

August 18, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.